Physiomics plc (Physiomics) is engaged in developing computational systems biology models for predicting and understanding cancer drug efficacy and finding optimal schedules. Physiomics provides consulting services for specific pharmaceutical development projects and provides trouble-shooting services for cancer projects in exchange for product licenses and royalties. Its key services include, designing optimal drug schedules, optimizing drug combinations, and Single-blind validation study. Physiomics partners with small and large pharmaceutical and biotechnology companies. These include Eli Lilly, Sareum, Cyclacel Pharmaceutical, Institute of Cancer Research, and ValiRx. The company is headquartered at Oxford in the UK.